Biology of Blood and Marrow Transplantation
Volume 13, Issue 10 , Pages 1224-1232 , October 2007

Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging

  • Alessandro Isidori

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • Hematology and Bone Marrow Transplant Center, San Salvatore Hospital, Pesaro, Italy
    • Corresponding Author InformationCorrespondence and reprint requests: Alessandro Isidori, MD, Hematology and Bone Marrow Transplant Center, San Salvatore Hospital, Via Lombroso, 61100 Pesaro, Italy.
    • ,
  • Maria Rosa Motta

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Monica Tani

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Carolina Terragna

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Pierluigi Zinzani

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Antonio Curti

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Simonetta Rizzi

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Simona Taioli

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Valeria Giudice

      Affiliations

    • Immunohematology Service and Blood Bank, S. Orsola-Malpighi Hospital, Bologna, Italy
    • ,
  • Alessandra D’Addio

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Gabriele Gugliotta

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Roberto Conte

      Affiliations

    • Immunohematology Service and Blood Bank, S. Orsola-Malpighi Hospital, Bologna, Italy
    • ,
  • Michele Baccarani

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy
    • ,
  • Roberto M. Lemoli

      Affiliations

    • Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” University of Bologna, Bologna, Italy

Received 2 May 2007 ,Accepted 10 July 2007.

References 

  1. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. Blood. 1997;90:5013
  2. Yin Ah, Miraglia S, Zanjiani ED. AC 133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002
  3. Bathia M. AC 133 expression in human stem cells. Leukemia. 2001;15:1685–1688
  4. Matsumoto K, Yasui K, Yamashita N, et al. In vitro proliferation potential of AC 133 positive cells in peripheral blood. Stem Cells. 2000;18:196–203
  5. Filip S, Vavrova J, Vokurova D, et al. Myeloid differentiation and maturation of SCF + IL-3 + IL-11 expanded AC133+/CD34+cells selected from high-risk breast cancer. Neoplasma. 2000;47:73–80
  6. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430–436
  7. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2+AC133+ endothelial precursors cells. Circ Res. 2001;88:167–174
  8. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000;95:952–958
  9. Kaufman DS, Hanson ET, Lewis RC, Auerbach R, Thomson JA. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA. 2001;98:10716–10721
  10. Kelly S, Bliss TM, Shah AK, et al. Transplanted human fetal neural stem cells survive, migrate and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci USA. 2004;101:11839–11844
  11. Kuci S, Wessels JT, Buhring H-J, et al. Identification of a novel class of human adherent CD34− stem cells that give rise to SCID-repopulating cells. Blood. 2003;101:869–876
  12. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–49
  13. Lang P, Bader P, Schumm M, et al. Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol. 2004;124:72–79
  14. Bitan M, Shapira MY, Resnick IB, et al. Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp Hematol. 2005;33:713–718
  15. Barfield RC, Hale GA, Burnette K, et al. Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48:349–353
  16. Diehl LF, Karnell LH, Menck HR, et al. The American College of Surgeons Commission on Cancer and The American Cancer Society (The National Cancer Data Base report on age, gender, treatment and outcomes of patients with chronic lymphocytic leukemia). Cancer. 1999;86:2684
  17. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005;90:391–399
  18. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;24:1750–1756
  19. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  20. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897
  21. Faderl S, Coutrè C, Byrd JC, et al. The evolving role of Alemtuzumab in management of patients with CLL. Leukemia. 2005;19:2147–2152
  22. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia (European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry). Ann Intern Med. 1996;124:311–315
  23. Khouri IF, Keating M, Korbling M, et al. Transplantlite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817–2824
  24. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;19:3819–3829
  25. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19:1029–1033
  26. Gribben JG. Salvage therapy for CLL and the role of stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2005;292-298.
  27. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82:1366–1376
  28. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106:4389–4396
  29. Milligan D, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005;105:397–404
  30. Dreger P, Viehmann K, von Neuhoff N, et al. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp Hematol. 2000;28:1187–1196
  31. Altes A, Sierra J, Esteve J, et al. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol. 2002;30:824–830
  32. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  33. Lemoli RM, Martinelli G, Zamagni E, et al. Engraftment, clinical and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95:2234–2239
  34. Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective to support myeloablative chemotherapy in patients with hematological malignancies and poor peripheral blood stem cell mobilization. Blood. 2003;102:1595–1600
  35. Lemoli RM, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating myeloma cells. Blood. 1996;87:1625–1634
  36. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18:2273–2281
  37. Shpall E, Champlin R, Glaspy J, et al. Effect of CD34+ peripheral progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant. 1999;24:1329–1336
  38. Dreger P, Viehmann K, von Neuhoff N, et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant. 1999;24:153–161
  39. Gahn B, Schafer C, Neef J, et al. Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood. 1997;89:4275–4281
  40. Ghan B, Wendenburg B, Troff C, et al. Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level. Br J Haematol. 1999;105:955–959

PII: S1083-8791(07)00347-3

doi: 10.1016/j.bbmt.2007.07.004

Biology of Blood and Marrow Transplantation
Volume 13, Issue 10 , Pages 1224-1232 , October 2007

Article Tools

* Image Usage & Resolution